Garden House USA

Garden House USA is the North American subsidiary of Kaken Pharmaceutical, a leading Japanese specialty pharmaceutical company. The firm was established to spearhead the clinical development and strategic licensing of Kaken's therapeutic portfolio within the United States market. Its primary focus areas include dermatology and orthopedics, leveraging the parent company's expertise in small molecules and regenerative medicine. Garden House USA is instrumental in managing regulatory pathways and identifying commercial partners for innovative treatments such as efinaconazole and trafermin. By serving as a bridge between Japanese R&D and the US healthcare system, the company aims to address unmet medical needs in wound care and skin diseases. The Emeryville-based office handles business development, clinical trial management, and alliance operations.